Health Discovery Corporation Launches Android Version of Popular MelApp, Melanoma Risk Analysis Mobile Phone App
02 February 2012 - 5:05AM
Business Wire
Health Discovery Corporation (OTCBB: HDVY), the molecular
diagnostics company that launched MelApp, the first SVM-based image
analysis iPhone app for melanoma risk assessment, today debuts its
popular MelApp mobile app for Android™ devices. Now,
health-conscious consumers can easily learn about melanoma and
identify areas on their skin which may need attention from a
specialist, anytime, anywhere with their iPhone, iPod Touch and
iPad, as well as Android smartphone.
First launched this summer for iPhone, MelApp uses highly
sophisticated patent protected mathematical algorithms and image
based pattern recognition technology to analyze an uploaded image.
The app was validated using an image database licensed from Johns
Hopkins University Medical Center and uses a device’s camera
feature to deliver a risk analysis of user’s photographed skin
lesions within seconds. In addition, MelApp can use the
smartphone’s GPS to refer users to physicians specializing in the
diagnosis and treatment of melanoma for proper medical diagnosis
and treatment.
“Being currently used in nearly 50 countries, and having been
named one of the ‘Top 10 Apps That Could Save Your Life’ in a
recent issue of Parade Magazine, MelApp has become a worldwide
success,” stated Stephen D. Barnhill, M.D. Chairman and CEO of
Health Discovery Corporation. “With the launch of MelApp for
Android our goal was to extend the availability of this easy to
use, inexpensive and potentially life-saving app to the more than
46 percent of the smart phone market that use Android devices,
according to Nielsen.”
Now available for iPhone, iPod touch, and iPad, as well as for
Android, MelApp is available for download at a special limited time
price of $1.99 at the following app marketplaces:
- iTunes App Store -
http://itunes.apple.com/us/app/melapp/id446669257?mt=8&ls=1
- Android Marketplace - https://market.android.com/search?q=MelApp&c=apps
This version of MelApp for Android has been optimized for the
Droid X. For support and technical inquiries, contact
support@healthdiscoverylabs.com.
Physicians who diagnose and treat melanoma can become a
subscribing member of HDC’s physician referral network by
contacting melappreferral@healthdiscoverycorp.com.
About MelApp & Health Discovery Corporation
MelApp uses highly sophisticated patent protected mathematical
algorithms and image based pattern recognition technology to
analyze the uploaded image. MelApp was validated using an image
database licensed from Johns Hopkins University Medical Center and
uses a device’s camera feature to deliver a risk analysis of user’s
photographed skin lesions within seconds. The app can use the
iPhone GPS to refer users to physicians specializing in the
diagnosis and treatment of melanoma for proper medical follow-up.
MelApp by Health Discovery Corporation is available at a special
limited time introductory price of $1.99. For more complete
details, visit http://www.melapp.net,
http://www.facebook.com/MelApp or
http://twitter.com/#!/SafeHealthApps.
Health Discovery Corporation is a molecular diagnostics company
that uses advanced mathematical techniques to analyze large amounts
of data to uncover patterns that might otherwise be undetectable.
It operates primarily in the emerging field of personalized
medicine where such tools are critical to scientific discovery. Its
primary business consists of licensing its intellectual property
and developing its own product line of biomarker-based diagnostic
tests that include human genes and genetic variations, as well as
gene, protein, and metabolic expression differences and image
analysis in digital pathology and radiology. For more information,
see www.healthdiscoverycorp.com.
Forward-Looking Statements
This document contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
the accuracy of which is necessarily subject to risks and
uncertainties, including, without limitation, statements regarding
future performance, opportunities and investments, and anticipated
results in general. From time to time the Company may make other
forward-looking statements in relation to other matters, including
without limitation, commercialization plans and strategic
partnerships. Actual results may differ materially due to a variety
of factors, including, among other things, the acceptance of our
approach to applying mathematics, computer science and physics into
the disciplines of biology, organic chemistry and medicine and our
products and technologies associated with those approaches, the
ability to develop and commercialize new drugs, therapies or other
products based on our approaches, and other factors set forth from
time to time in the Company’s Securities and Exchange Commission
filings.
All forward-looking statements and cautionary statements
included in this document are made as of the date hereof based on
information available to the Company as of the date hereof, and the
Company assumes no obligation to update any forward-looking
statement or cautionary statement.
Health Discovery (CE) (USOTC:HDVY)
Historical Stock Chart
From Jan 2025 to Feb 2025
Health Discovery (CE) (USOTC:HDVY)
Historical Stock Chart
From Feb 2024 to Feb 2025